Allianz Asset Management GmbH Purchases 30,537 Shares of Jazz Pharmaceuticals PLC $JAZZ

Allianz Asset Management GmbH lifted its position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 9.4% in the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 355,940 shares of the specialty pharmaceutical company’s stock after acquiring an additional 30,537 shares during the period. Allianz Asset Management GmbH owned 0.59% of Jazz Pharmaceuticals worth $46,913,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Kennedy Capital Management LLC acquired a new stake in shares of Jazz Pharmaceuticals during the 2nd quarter worth approximately $1,100,000. Wedge Capital Management L L P NC acquired a new position in Jazz Pharmaceuticals in the third quarter valued at approximately $27,834,000. Sequoia Financial Advisors LLC acquired a new position in shares of Jazz Pharmaceuticals in the 3rd quarter worth approximately $605,000. Measured Wealth Private Client Group LLC lifted its position in shares of Jazz Pharmaceuticals by 47.1% during the second quarter. Measured Wealth Private Client Group LLC now owns 4,855 shares of the specialty pharmaceutical company’s stock worth $515,000 after purchasing an additional 1,554 shares in the last quarter. Finally, Schroder Investment Management Group grew its position in shares of Jazz Pharmaceuticals by 90.1% during the second quarter. Schroder Investment Management Group now owns 17,816 shares of the specialty pharmaceutical company’s stock worth $1,891,000 after buying an additional 8,444 shares in the last quarter. 89.14% of the stock is currently owned by institutional investors.

Trending Headlines about Jazz Pharmaceuticals

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Zacks raised its FY2027 EPS estimate to $20.06 (from $19.95), signaling stronger long‑term earnings expectations. MarketBeat Report
• Positive Sentiment: Zacks increased Q4 2027 EPS to $5.50 (from $5.45), a small lift that supports the FY2027 upgrade. MarketBeat Report
• Positive Sentiment: Zacks nudged up Q3 2027 to $5.70 (from $5.66) and Q2 2027 to $5.04 (from $5.03), indicating incremental confidence in mid‑2027 results. MarketBeat Report
• Positive Sentiment: Zacks raised Q4 2026 to $5.00 (from $4.96) and Q1 2027 to $3.82 (from $3.80), small upward tweaks to near‑term quarters. MarketBeat Report
• Negative Sentiment: Zacks trimmed Q3 2026 slightly to $5.25 (from $5.26) and cut Q2 2026 to $4.88 (from $4.90), modest downgrades to some nearer‑term quarters. MarketBeat Report
• Negative Sentiment: Zacks also nudged Q4 2025 down to $5.15 (from $5.16); these cuts are very small but contribute to the mixed picture. MarketBeat Report

Jazz Pharmaceuticals Stock Performance

Shares of NASDAQ JAZZ opened at $165.72 on Thursday. Jazz Pharmaceuticals PLC has a 52-week low of $95.49 and a 52-week high of $182.99. The stock’s fifty day simple moving average is $168.36 and its 200 day simple moving average is $144.82. The company has a quick ratio of 1.44, a current ratio of 1.65 and a debt-to-equity ratio of 1.09. The stock has a market capitalization of $10.07 billion, a price-to-earnings ratio of -27.30, a PEG ratio of 0.90 and a beta of 0.26.

Analysts Set New Price Targets

JAZZ has been the subject of a number of research reports. TD Cowen reiterated a “buy” rating on shares of Jazz Pharmaceuticals in a research note on Thursday, January 29th. Royal Bank Of Canada set a $194.00 price objective on shares of Jazz Pharmaceuticals and gave the company an “outperform” rating in a research report on Monday, November 17th. Wall Street Zen raised Jazz Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Saturday, November 8th. UBS Group restated a “neutral” rating and issued a $188.00 price target (up previously from $163.00) on shares of Jazz Pharmaceuticals in a report on Monday, November 24th. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a report on Monday, December 29th. Fourteen analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Jazz Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $205.67.

Insiders Place Their Bets

In related news, Director Bruce C. Cozadd sold 77,500 shares of the firm’s stock in a transaction that occurred on Wednesday, November 26th. The shares were sold at an average price of $177.81, for a total transaction of $13,780,275.00. Following the completion of the sale, the director directly owned 393,332 shares in the company, valued at approximately $69,938,362.92. This trade represents a 16.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CAO Patricia Carr sold 4,660 shares of Jazz Pharmaceuticals stock in a transaction on Friday, December 5th. The shares were sold at an average price of $171.20, for a total value of $797,792.00. Following the sale, the chief accounting officer directly owned 7,012 shares of the company’s stock, valued at approximately $1,200,454.40. The trade was a 39.92% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 123,791 shares of company stock valued at $21,991,850 over the last ninety days. Insiders own 4.30% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.